CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
Biomolecules and Biomedicine · 02.05.2024 · 24 (3) · 465-476
DOI: 10.17305/bb.2023.9675 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 02.05.2024. Verfasst von Kun Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Macrophages. Die Arbeit wurde bisher 43-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adoptive cell therapy (ACT) has been demonstrated to be one of the most promising cancer immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells to overexpress chimeric antigen receptors (CARs), for example, has shown potent efficacy in the therapy of some hematologic malignancies. However, the efficacy of chimeric antigen receptor T cell (CAR-T) therapy against solid tumors is still limited due to the immunosuppressive tumor microenvironment (TME) of solid tumors, difficulty in infiltrating tumor sites, lack of tumor-specific antigens, antigen escape, and severe side effects. In contrast, macrophages expressing CARs (CAR-macrophages) have emerged as another promising candidate in immunotherapy, particularly for solid tumors. Now at its nascent stage (with only one clinical trial progressing), CAR-macrophage still shows inspiring potential advantages over CAR-T in treating solid tumors, including more abundant antitumor mechanisms and better infiltration into tumors. In this review, we discuss the relationships and differences between CAR-T and CAR-macrophage therapies in terms of their CAR structures, antitumor mechanisms, challenges faced in treating solid tumors, and insights gleaned from clinical trials and practice for solid tumors. We especially highlight the potential advantages of CAR-macrophage therapy over CAR-T for solid tumors. Understanding these relationships and differences provides new insight into possible optimization strategies of both these two therapies in solid tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Sun Yat-sen University, Shenzhen, China.
- Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Zitieren
APA
Chen, K., Liu, M. L., Wang, J. C., & Fang, S. (2024). CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar. Biomolecules and Biomedicine, 24(3), 465-476. https://doi.org/10.17305/bb.2023.9675
Vancouver
Chen K, Liu ML, Wang JC, Fang S. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar. Biomolecules and Biomedicine. 2024;24(3):465-476. doi:10.17305/bb.2023.9675
BibTeX
@article{Chen2024,
author = {Chen, Kun and Liu, Min-Ling and Wang, Jian-Cheng and Fang, Shuo},
title = {CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar},
journal = {Biomolecules and Biomedicine},
year = {2024},
volume = {24},
number = {3},
pages = {465--476},
doi = {10.17305/bb.2023.9675}
}
EUVIMED